Request form

Please enclose this completed examination form with your sample shipment. The form represents all diagnostic methods and analyses completely.

Request form hemoglobinopathy

Order for laboratory and molecular genetic testing for hemoglobinopathies.

Patient consent - Research projects

By providing this patient consent, you agree to the use of excess biomaterial for research purposes.

Primary sample collection manual

Detailed information on test material and shipment can be found in our primary sample collection manual.

Information for correct sampling of buccal swap and nail material

Here you will find information on the correct sampling of germline material.

MLL News 2023 (4)

MLL staging diagnostics for unclear cytopenia / The MLL introduces itself - our medical documentation / Clonal hematopoiesis risk score

MLL News 2023 (3)

MLL is "Innovator of the Year" in TOP 100 innovation competition / Screening for Sézary syndrome in cases of confirmed mycosis fungoides / Events at MLL: MLL-Academy 2023 & Advanced Training "From Myeloma to MDS" of the Genome Network Hematology / Myeloid neoplasms with familial predisposition

MLL News 2023 (2)

Rethinking diagnostics and research: Our AI team introduces itself / Diagnostic potential of immunophenotypic aberrations in MDS / BAX mutations mediate venetoclax resistance in AML / Update: the Onkopedia recommendations on chronic lymphocytic leukemia (CLL)

MLL News 2023 (1)

New: The Genome Network Hematology introduces itself / Hemoglobinopathies - thalassemias and abnormal hemoglobins / The new knowledge management at MLL / All about our renewed award as Top Innovator / Research Report 2022 / Current events: MLL Academy and MADE - Microscopy Courses

MLL News 2022 (6)

We want to say thank you: The MLL Annual Review for 2022 / MLL at the 64th ASH Annual Meeting & Exposition – a Follow-Up Report / Transcriptome Analysis with B-ALL and MLN-TK / WHO, ELN and IPSS-M: Adjusting Our Diagnostic Service

MLL News 2022 (5)

1,000,000 Samples Since the MLL Was Founded / New: Quick Request Option for MLL Order Entry / Chromosome Analysis 5.0 – Automation, Digitization, and Artificial Intelligence / MLL Introduces Itself: Our Quality Management

MLL News 2022 (4)

Follow-up report on the training course “The new WHO classification” on July 27, 2022, in the MLL Munich Leukemia Laboratory / Reactive versus neoplastic – New panel to clarify clonal T-cell populations / IPSS-M: Molecular International Prognostic Scoring System

MLL News 2022 (3)

The new WHO-Classification / MLL Introduces Itself: Our HR Department / Events at MLL - Looking back

MLL News 2022 (2)

Our new website has arrived / Validation of the laboratory-specific conversion factor for BCR::ABL1 p210 / The contact point for all departments – the MLL Secretariat – introduces itself

MLL News 2022 (1)

CHIP highly relevant to individual risk profile for individuals aged ≥80 years / CLL: The more complex the karyotype, the less favorable the prognosis / Client communication and digital portals – Introducing our customer support

MLL News 2021 (6)

We Want to Say Thank You: The MLL Annual Review for 2021 / Hematological Whole Genome and Transcriptome Sequencing as a New Diagnostic Tool for Acute Leukemias / 63rd ASH Annual Meeting & Exposition – a Postscript / MLL Dx Successfully Accredited by the College of American Pathologists (CAP)

MLL News 2021 (5)

A Difficult Case: What the Diagnostics of Tomorrow Will Look Like / We value your opinion! / From Genome to Exome to RNA Sequencing – an Interview Regarding
Our New MLLSEQ Sequencing Service / Good Findings Start with Preanalytics – Our Sample Receipt Area Introduces Itself

MLL News 2021 (4)

MLL and Institute of AI for Health of the Helmholtz Center of Munich Announce Research Collaboration / Our First Whole Genome Sequencing Report / MTLAs, doctors and artificial intelligence at MLL – a good team! / Medical Work at the Munich Leukemia Laboratory / MHP Becomes MLL MVZ GmbH

MLL News 2021 (3)

4-stage (4-tier) system for evaluating sequence variants / MLLSEQ—our sequencing service has a new look / The logic of next generation sequencing wherever myeloid neoplasia is
suspected / Novel aspects of the MLL website in the area “Diseases/Diagnostics”

MLL News 2021 (2)

New panel for clarifying unclear erythrocytosis/polyglobulia / Advances in the targeted therapy of lymphoma / MLL findings portal: Here you can view your findings online

MLL News 2021 (1)

An ISO 14001 certified environmental management system for sustainable and environmentally friendly leukemia diagnostics / The MLL is listed in BAYERN’S BEST 50 and was recognized as the Top Innovator for
2021 / 62. ASH Annual Meeting & Exposition - a follow-up report / Presentation: The MHP Munich Hematology Practice

MLL News 2020 (5)

Merry Christmas! / Molecular genetics in mastocytosis and hypereosinophilia / Advances in the targeted therapy of hematological neoplasias

MLL News 2020 (4)

Pharmacogenetic Fluorouracil Toxicity Testing at MLL / BELUGA - A prospective, Registered Study on the Use of Artificial Intelligence (AI) in Hematology / We value your opinion! / On our own behalf: Optimizing the quality of service / MDS-Associated Aberrant Phenotypes in Multiple Myeloma

MLL News 2020 (3)

15 Years of MLL: an anniversary without celebrations / MLL Dx - the new website is live / Diagnostic perspectives - WGS and WTS

MLL News 2020 (2)

Leukemia diagnostics during the pandemic / Identifying resistance mutations in targeted therapies / MLL uses AWS Cloud Computing infrastructure for NGS data

MLL News 2020 (1)

New MLL Findings Portal Allows Findings to be Viewed Online / Assessing Sequence Variants / The Use of Artificial Intelligence at MLL

MLL News 2019 (5)

A very Merry Christmas from MLL! / MLL Developing a Digital Order Entry Platform / Video Tutorial on the Intelligent PDF Versin of the Test Request / Successful Participation by MLL in the ASH Conference in Orlando / MLL Academy - Workshop on Next-Generation Sequencing

Accreditation Certificate DIN EN ISO 15189

The MLL MVZ has been accredited for medical laboratory diagnostics according to DIN EN ISO 15189:2014 since 2009 and always works according to these high quality standards.

Accreditation Certificate DIN EN ISO/IEC 17025

MLL has been accredited in accordance with DIN EN ISO/IEC 17025 for testing laboratories since 2009 and carries out tests in the field of healthcare (medical laboratory tests as part of clinical studies).

College of American Pathologists

MLL Dx GmbH has been accredited by the College of American Pathologists in 2021 and always works according to these quality standards.

Certificate of the MDS Center of Excellence

MLL has been recognized as a Center of Excellence in the diagnosis and treatment of the myelodysplastic syndromes.

CAP proficiency testing program

MLL Dx successfully participates in the CAP proficiency testing program for various analyses and methods.

Certificate ERIC IGHV

MLL meets the highest ERIC (European Research Initiative on CLL) standards for immunoglobulin (IG) mutation detection and interpretation.

Certificate ERIC TP53

MLL meets the highest ERIC (European Research Initiative on CLL) standards for detection and interpretation of TP53 mutations.

UK NEQAS Molecular genetics

MLL successfully participates in the "Molecular Haemato-oncology programs" for various analyses and methods.

UK NEQAS Immunophenotyping

MLL successfully participates in the "Flow Cytometry Programs" for PNH.

German Medical Association (BÄK) Guidelines on Quality Assurance (german)

Guideline of the German Medical Association for Quality Assurance of Laboratory Medical Examinations - Rili-BÄK (according to resolution of 23.04.2023).

Certificate enviromental management DEKRA: ISO 14001:2015

MLL has implemented and successfully maintains an environmental management system in accordance with the aforementioned standard.

List of flexibly accredited analytes

last update: 23rd of January 2023

09/2023 - MLL Munich Leukemia Laboratory in the final of the "EY Entrepreneur Of The Year 2023" competition

09/2023 - Germany's most innovative medium-sized companies: MLL Munich Leukemia Laboratory with successful placement

04/2022 - MLL and Institute of AI for Health of the Helmholtz Center of Munich

07/2021 - MLLSEQ: New sequencing service of the MLL Munich Leukemia Laboratory

06/2020 - MLL chosen as innovation champion TOP100 (247 KB)

12/2019 - MLL developing digital order entry platform (509 KB)

06/2019 - MLL is one of Germanys TOP100 (263 KB)

12/2018 - MLLi database project for improved leukemia diagnostics (360 KB)

06/2018 - Prof. Torsten Haferlach establishes non-profit leukemia diagnostics foundation (349 KB)

05/2018 - MLL launches its new corporate identity (589 KB)

12/2017 - MLL launches integrated report (421 KB)

MLL corporate brochure (983 KB)

See behind. Go beyond. We believe that extraordinary things emerge through the blending of knowledge, courage and responsibility. In this brochure we have summarised what this means at our company.

MLL corporate brochure - Science and research (449 KB)

Sharing knowledge. Advancing science. Under this motto, research also has a high priority at MLL. Here you will find an overview of our research focus and activities.

MLL corporate brochure - Pharma (508 KB)

We are a reliable partner for clinical studies. Here you will find a summary of our services.